Full Report

Know the Business — Supreme plc (SUP)

Supreme is a UK FMCG distributor that has, almost by accident, become a vertically integrated brand owner. The economic engine is a value-priced, high-velocity, low-assortment platform that sells whatever its retail customers (B&M, Home Bargains, Poundland, Tesco, Sainsbury's, Asda, Aldi) will put on the shelf at a sub-premium price. The market currently underestimates two things: (1) that Vaping is a cash machine even after the disposable ban, and (2) that "branded distribution" margin compression hides genuine operating leverage on the in-house manufactured base.

How This Business Actually Works

Supreme makes money in three different ways inside one corporate skin, and confusing them is the most common analytical error.

The Electricals business (Duracell, Energizer, Panasonic batteries plus licensed lighting under Eveready, Black & Decker, JCB) is a low-margin, low-overhead door-opener. Roughly 35% UK battery share, near-zero incremental cost — it earns Supreme its slot in every retailer's electrical aisle. Drinks & Wellness (SCI-MX sports nutrition, vitamins, plus the FY24 Clearly Drinks and FY25 Typhoo Tea / SlimFast acquisitions) is an in-house manufactured branded-goods business with classic FMCG margins. Vaping — both 88Vape (own-brand, manufactured at up to 4.5 million bottles of e-liquid per week) and the master distribution agreement for ElfBar / Lost Mary — is the cash engine: 56% of FY25 revenue, 36% gross margin on the owned half, much thinner on the third-party distribution half.

Incremental profit comes overwhelmingly from two things: (1) cross-selling new categories down the existing customer pipeline, where overhead barely moves; and (2) acquiring brands (Battle Bites, SCI-MX, Liberty Flights, Cuts Ice, Clearly Drinks, Typhoo Tea, SlimFast) at 2-4x post-synergy EBITDA and putting them through the central platform. Bargaining power is modest with the big grocers but strong with discounters, where Supreme's price/quality combination has become structurally important.

The Playing Field

There is no clean comp. Supreme is a hybrid of a soft-drinks brand owner, a private-label household manufacturer, and a vape distributor — so peers are read across three industries.

What the peer set reveals: Supreme earns soft-drink-like ROCE (around 40%) on McBride-like revenue per pound of capital, while trading at McBride's multiple. Nichols (Vimto) and AG Barr (Irn-Bru) are the real anchors — branded UK FMCG businesses with similar margin shape but trade at roughly twice the EV/EBITDA. Applied Nutrition has the cleanest single-category profile and the highest margin of the group, which is why it earns a 10x+ multiple. McBride is the cautionary tale: high ROCE only because equity has been depleted; the low multiple reflects that. The "good" version of Supreme is a Nichols-margin, BAG-multiple business — a path that depends on Drinks & Wellness, not Vaping, becoming the dominant gross-profit pool.

Is This Business Cyclical?

Mildly cyclical at the topline, far less cyclical at the gross-profit line, and almost not cyclical at the cash-flow line — because the categories are consumer staples sold predominantly through value retailers that thrive in downturns.

The two cycles that actually matter for Supreme are not GDP cycles — they are regulatory and inventory. The 2023 lighting collapse (43% revenue decline that year) was a customer-destocking event, not end-demand. The 2024-2026 vaping cycle has been a regulatory transition: HMRC excise duty proposed in 2024, disposable ban effective June 2025, vape levy due October 2026. Disposable revenue dropped from £71m (FY24) to £54m (FY25); the company guided this carefully and avoided stock writedowns. Working capital and inventory turnover behavior has been noisy because of this — inventory turnover ran from 6.3x in FY24 to 5.2x in FY25 as the mix transitioned to pods.

The lesson: the bottom-line shock from a regulatory event is much smaller than the headline revenue shock, because (a) the disposable consumer migrates to refillable pods at the same price point with a similar gross-margin profile, and (b) discounters absorb price increases on staples categories.

The Metrics That Actually Matter

Three metrics carry almost all the signal. Forget reported P/E in isolation.

P/E and EV/Sales miss the point. Supreme's reported P/E of around 8x is meaningless without segmenting Vaping cash from non-Vaping cash. The right way to think about it is: how many pounds of gross profit does the central platform generate per pound of SG&A overhead, and how does that ratio scale as the next acquisition is bolted on. That ratio sits at 16-20x and has not deteriorated as the company tripled in size.

What Is This Business Worth?

Supreme is best valued as two distinct economic engines under one roof — and the consolidated multiple deserves to be a weighted blend, not a single number. Vaping is a regulated, terminal-value-impaired cash cow worth a low-single-digit EBITDA multiple. The non-Vaping platform (Drinks & Wellness + Electricals + central platform leverage) deserves a mid-teens earnings multiple consistent with Nichols and AG Barr.

The stock makes sense if Drinks & Wellness compounds into the dominant gross-profit pool over the next three years; it does not make sense if Vaping is the entire thesis. The market is pricing it as the latter. The single number that would justify a re-rating to a Nichols/BAG multiple is non-Vaping gross profit crossing £40m — at FY25 it was around £25m, growing fast through M&A.

What I'd Tell a Young Analyst

Watch gross profit by category, not revenue. Watch acquisition multiples, not deal counts. Watch the ratio of gross profit to SG&A — if Supreme's platform thesis is real, that ratio holds steady as the company grows; if it's a typical roll-up, it collapses. Three things would change the thesis: (1) a Sandy Chadha succession event (he's both the operator and the deal sourcer — concentrated key-person risk), (2) a vaping levy structure that taxes refillable pods as harshly as disposables (currently expected to be lighter), (3) signs that any acquisition is being integrated badly — measured by gross margin compression in the acquired category 12 months in. The cleanest bull/bear test is the FY26 guidance for Drinks & Wellness gross profit. Below £15m: the diversification story is stalling. Above £20m: Supreme is no longer a vape stock.

Supreme plc — The Numbers

Supreme is a UK FMCG distributor that earns money buying batteries, vaping, lighting, sports nutrition and household goods at scale and pushing them through grocers, discounters and convenience. The business has roughly doubled revenue in five years to £231M while operating margin has rebuilt to 14.1% — yet the equity trades at about 8x earnings and 4.5x EBITDA, levels normally seen at structurally challenged distributors. The single metric most likely to rerate or derate this stock is vaping revenue durability post the June 2025 UK disposable-vape ban: if nicotine pouches and refillable vapes hold the segment flat, the multiple compresses upward toward the 12x five-year mean; if vaping shrinks, the cheap multiple is justified.

A. Snapshot strip

A consensus analyst price target sits near £2.25, implying ~40% upside; the question is whether the market simply does not believe FY26 numbers will hold.

B. Quality scorecard — is this business well-run and durable?

The scorecard says this is a high-quality, conservatively-financed distributor. ROIC of 30% and EBIT/interest of 18x are not what bankrupt or fading businesses look like; the only blemish is that ROA, current ratio and asset turnover all dipped year-over-year as the FY25 Clearly Drinks acquisition expanded the asset base ahead of revenue catching up.

C. Revenue & earnings power — six-year view

The FY24 step-change came from vaping volumes following the 2023 nicotine-pouch and 88vape rollout into Tesco/Asda. FY25 revenue growth slowed to 4.4% YoY but gross margin expanded 320bps to 31.9% — the highest in the printed history — because the acquired Clearly Drinks business and own-brand vaping carry better unit economics than third-party batteries.

D. Cash generation — are the earnings real?

Cash conversion is clean: trailing five-year FCF / Net Income averages 1.04 and CFO / NI averages 1.20 — there are no SBC or working-capital tricks puffing reported profit. Capex stays under 2.4% of revenue even with the FY24 manufacturing build-out, which is the right shape for a distributor with low fixed-asset intensity.

E. Capital allocation

FY25 spent £25.6M on the Clearly Drinks acquisition, the largest deal in company history; the dividend was raised modestly while buybacks were minimal. Allocation is tilted toward bolt-on M&A and a steady ~30% payout ratio — sensible discipline given the founder-CEO still owns roughly a quarter of the company.

F. Balance sheet health

G. Valuation — now vs its own history (the most important visual)

The stock collapsed from 244p in mid-2022 to a 74p low in late-2022 on cost-of-living and disposable-vape regulatory fears, then recovered to a 205p peak in mid-2025 as FY24 results vindicated the vaping pivot, then gave back ~30% on 2025-2026 disposable ban headlines and FY25 deceleration. At 160p the multiple is a third below its own five-year mean and well below where revenue and ROIC say it should sit.

H. Peer comparison — UK Consumer Staples

Supreme posts operating margin in line with AG Barr (14.1%) and ROE materially above every UK peer (35% vs 8-39%) but trades at less than half the EV/EBITDA of branded comparables AG Barr (11x), Nichols (9.5x) and Applied Nutrition (9x), and at a discount even to lower-quality McBride. The peer gap exists because the market still treats Supreme as a one-trick vaping play, not as a multi-category FMCG distributor.

I. Fair value & scenario

The asymmetry is favorable: at 160p the stock is 11% below the bear case, and the base case implies 50% upside. The scenarios that need to play out for the bear case are real (vape compliance costs, retailer destocking) but already partially priced in — the disposable ban came into force in June 2025 and FY25 numbers absorbed it.

Closing

The numbers confirm that Supreme is a high-quality FMCG distributor: 30% ROIC, 20% five-year revenue CAGR, 1.04 FCF/NI conversion, and a balance sheet with 0.3x net leverage that could fund another £30-40M bolt-on without strain. The numbers contradict the popular framing that this is a fragile vaping pure-play: gross margin just printed an all-time high of 31.9% as the mix shifted toward sports nutrition, branded soft drinks (Clearly) and refillable vapes — exactly the diversification the regulator-fear narrative claims is not happening. Watch FY26 H1 vaping revenue (June 2026 print) — if vaping holds within 10% of FY25 levels under the disposable ban, the multiple gap to UK FMCG peers (currently ~50%) is the single biggest source of return; if vaping falls 25%+, the bear case takes over and the rerating thesis dies for another year.

Where We Disagree With the Market

The market is pricing Supreme as a vape distributor with a regulatory ceiling. Our evidence says it is a 30%-plus ROIC FMCG distribution platform that has bought four UK consumer brands at sub-3x post-synergy EBITDA in fourteen months — but the same evidence forces a second, less comfortable disagreement: consensus is also extrapolating FY25 cash quality, and FY25 acquisition-adjusted free cash flow was actually negative £3.65m. Both views can be right: the platform is misclassified, and the cash conversion is being financed by working-capital draws and debt headroom rather than recurring cash. The single resolving signal is the FY26 print in late June 2026 — non-vape gross profit at or above £40m and a return to positive acquisition-adjusted FCF would settle the rerating debate; either failing settles it the other way. If we are right on platform classification but wrong on cash quality, the stock still rerates; if we are wrong on platform but right on cash quality, the bear case prints. The interesting trade is where both legs resolve in the same direction.

Variant Perception Scorecard

The 68 variant strength reflects two materially divergent disagreements that move valuation by more than 30% in either direction, both anchored to dated resolving events inside six months. Consensus clarity is high because the gap between the 7.79x P/E print and the 12.18x five-year mean, the 229.5p Fintel consensus target versus the 160p tape, and the FY25 EPS-versus-consensus history are all observable. Evidence strength is the weakest leg — the cleanest contradicting evidence (acquisition-adjusted FCF, segment gross-profit run-rates, acquisition multiples) is well-documented in the upstream tabs but partly model-implied rather than directly disclosed. The six-month resolution window is the FY26 full-year print plus the autumn 2026 vape excise levy.

Consensus Map

The consensus map shows where the market signal is strongest (vape overhang, founder alignment) versus where it is genuinely mixed (cash conversion, Drinks & Wellness optionality). High-clarity disagreements are higher-leverage; low-clarity ones are sizing inputs.

The Disagreement Ledger

Disagreement 1 — Mis-categorised platform. Consensus says Supreme is a UK vape distributor whose terminal value is capped by HMRC and whose earnings deserve a regulated-distributor multiple in the low single digits of EBITDA — that is the only framing that justifies trading at half the EV/EBITDA of AG Barr and Nichols on margins that are now in line. Our evidence says the engine of value creation is the platform itself: ROCE held at 39.7% in FY25, the gross-profit-to-overhead ratio has not deteriorated as revenue tripled, and four bolt-ons have closed at 2-4x post-synergy EBITDA in fourteen months — that is a Constellation-style compounding pattern, not a single-category distributor. If we are right, the market has to concede that 50%-plus of forward revenue is in branded FMCG categories with margin profiles that read across to Vimto/Irn-Bru, not to JT International, and the multiple gap to those peers (currently approximately 50%) closes inside 12-18 months. The cleanest disconfirming signal is the FY26 print: if non-vape gross profit comes in below £30m, the Drinks & Wellness platform thesis is stalling and the vape-pure-play framing was right.

Disagreement 2 — Cash quality is worse than headlines. Consensus reads the 12.3% FCF yield, the 1.04x FCF/Net Income, and the £40m HSBC facility headroom as evidence of a self-funding compounder; the 229.5p Fintel target only works if the dividend is paid out of recurring cash and M&A is not being financed by working-capital extraction. Our evidence says FY25 CFO £25.1m and acquisition spend £25.6m mean acquisition-adjusted FCF was negative £3.65m, year-end cash fell from £11.6m to £3.2m, and FY26 added two more deals (SlimFast £20.1m, 1001) requiring the first HSBC ABL drawdown the company has ever needed. If we are right, the market has to concede that the flywheel is debt-financed — which does not break the thesis, but does compress the multiple a serial acquirer with negative organic FCF can support. The cleanest disconfirming signal is FY26 acquisition-adjusted FCF: a return to at least +£10m says the FY25 print was the M&A-bunching artifact management claims; a second consecutive negative year says it is structural.

Disagreement 3 — Governance discount is real. Consensus treats the 56% founder stake as a 7.5/10 alignment positive — the same number people-claude assigns. Our evidence says the same tab flags four offsetting items the consensus discount does not weight: the 11-year BDO relationship is overdue for tender (FRC ethical standard for FTSE 350; AIM is exempt but the spirit applies), the 3-year LTIP was replaced with a 1-year SIP at 93.33% FY25 payout, there is no internal audit function, and Sandy Chadha placed shares twice in fourteen months at flat-to-discount prices. If we are right, AIM/QCA peers with similar profiles trade at a 1-2x EV/EBITDA governance discount — roughly 15-25% of share price — which narrows only when BDO is tendered and a multi-year LTIP is reinstated. The cleanest disconfirming signal is the AGM 2026 vote: free-float dissent above 25% on either Resolution 2 or Resolution 8 forces a board commitment; below 10% confirms minorities accept the package and the discount is unlikely to close on governance alone.

Disagreement 4 — Pod margin step-down erodes earnings, not just optics. Consensus reads H1 FY26 vape +13% as proof the substitution worked. Our evidence says the same release flagged a 200bps gross-margin step-down (33% to 31%) on a segment that is 56% of group revenue — roughly £2.6m of segment gross profit at FY25 scale, plus the FY26 EBITDA margin guide is 15% versus the FY25 17.5% print. If we are right, headline revenue durability is masking gross-profit erosion that the levy in October 2026 may then compound. The cleanest disconfirming signal is the FY26 segment gross margin disclosure: above 30% confirms the substitution thesis at the gross-profit line; below 28% says the disposables-margin era is gone in pounds, not just in mix.

Evidence That Changes the Odds

The strongest single piece of evidence is the acquisition-adjusted FCF print — it reframes the cash conversion narrative without rewriting any reported number. The weakest is the governance discount stack, where the AGM has never printed material dissent at SUP and minorities may simply tolerate the structure. The mis-categorisation argument depends on the FY26 non-vape gross profit print clearing £40m; below £30m, the platform thesis is intellectually correct but economically inert.

How This Gets Resolved

Five of the eight signals resolve at the same FY26 print in late June 2026 — the catalyst calendar concentrates the rerating debate into a single information event. The autumn 2026 levy is the higher-magnitude tail; the AGM and the placement risk are credibility tests rather than thesis-resolvers.

What Would Make Us Wrong

The mis-categorisation thesis would be wrong if the FY26 print shows non-vape gross profit stuck near £25-30m — that would mean Drinks & Wellness has not scaled despite the £25.6m of FY25 acquisition spend, despite Clearly Drinks consolidating for a full year, and despite the SlimFast/1001 contributions starting to land. In that case, the market is correctly anchoring on vape because vape is still mathematically the dominant gross-profit pool, and the platform-leverage argument is intellectually correct but economically inert. The right multiple under that scenario is closer to 5-6x EV/EBITDA — about where SUP trades today — and the disagreement collapses.

The cash quality thesis would be wrong if FY26 acquisition-adjusted FCF turns positive at +£10m or above, DSO normalises below 55 days, and the SlimFast purchase price is recovered through inventory and receivables release rather than ABL drawdown. The pattern would then look like: a single-year M&A-bunching event in FY25 (Clearly Drinks plus Typhoo plus working-capital build of £18.5m all hitting one fiscal year), followed by a return to recurring FCF that funds the dividend and bolt-on M&A. If that prints, our negative-FCF concern was real but transitional, and the bull case earns its 12x mean-reversion multiple.

The governance discount thesis would be wrong if the AGM 2026 produces no dissent on either BDO or the SIP, and the next bolt-on closes at sub-4x post-synergy EBITDA with cash funding (no further ABL drawdown). The track record then says: founder concentration is genuinely an alignment positive at SUP because the operator has demonstrated capital-allocation discipline through three transformations and two regulatory cycles. We would still flag the structural items in people-claude, but the discount we are arguing for would be intellectually defensible without being economically realised — which is the textbook case where governance theory loses to operating evidence.

The pod-margin thesis would be wrong if the FY26 vape segment gross margin recovers above 32% as the ElfBar Pod ramps and the disposable inventory headwind washes through. The H1 FY26 step-down would then look like a transition cost, not a structural floor; the FY26 EBITDA margin would beat the 15% guide rather than print to it; and the substitution narrative would be vindicated at both the revenue and the gross-profit line. That is the regime that takes the stock to the bull-case £3.20.

The first thing to watch is the FY26 non-vape gross-profit segment disclosure in late June 2026 — that single number, more than vape revenue, more than DSO, more than the levy, decides whether Supreme is a misclassified platform or a vape stock that bought some brands.

Bull and Bear

Verdict: Lean Long, Wait For Confirmation — the substitution mechanic worked through the disposables ban, but FY25 acquisition-adjusted free cash flow of negative £3.65m was real, the H1 FY26 print is the gating data point, and a 56% controlling founder on a one-year SIP with no internal audit raises the bar for ownership without confirmation. Bull carries more weight on operating evidence: 31.9% all-time-high gross margin, vape +13% YoY through the pod transition, 0.3x net leverage. Bear carries weight on the cash-quality and governance ledger that the bull does not address head-on. The deciding tension is the FY25 £25.6m of acquisition spend that nearly equals the £25.1m of CFO — both sides agree on the number; they disagree on whether it is a flywheel or a financing tell. The H1 FY26 release (late November 2025) — DSO and acquisition-adjusted FCF specifically — is what flips the verdict.

Bull Case

Bull's price target is £2.40 on a 12x P/E (the 5-year mean) applied to FY26 EPS of £0.20, with cross-checks to £2.62 on EV/EBITDA reversion to 7.65x and the £2.25-2.29 sell-side band. Timeline: 12-15 months. Disconfirming signal: FY26 vape revenue down more than 25% YoY, or DSO holding above 65 days at the H1 FY26 print, signaling that the receivables build is structural rather than acquisition-timing.

Bear Case

Bear's downside target is £1.05 on a stressed sum-of-the-parts (vape £15m EBITDA × 4x post-October-2026 levy, drinks £11m × 8x, electricals £9m × 5x, less £12m net debt and a £15m goodwill haircut on Clearly Drinks), cross-checked at 7x stressed FY27 EPS of £0.15. Timeline: 12-15 months through the H1 FY26 print, FY26 full year, and the October 2026 vape levy enactment. Cover signal: non-vape gross profit run-rates above £40m on the FY26 print and acquisition-adjusted FCF returns to positive £10m+.

The Real Debate

Verdict

Lean Long, Wait For Confirmation. Bull carries the operating debate: a 31.9% all-time-high gross margin, vape +13% YoY through the disposables ban, 0.3x net leverage, and a 36% mean-reversion gap on a five-year multiple history are not an accident. Bear carries the cash-quality and governance debate: FY25 acquisition-adjusted FCF of negative £3.65m, a £2.9m bargain-purchase gain inside the bonus formula, and an 11-year audit relationship with no internal audit are not things the bull rebuts. The deciding tension is the £25.6m of FY25 acquisition spend that nearly matches £25.1m of CFO — both sides own the same number and read it differently. The bear could still be right if the H1 FY26 print shows DSO holding above 60 days and another year-end cash draw, because that confirms the flywheel is debt-financed rather than cash-financed. The verdict flips to Lean Long on H1 FY26 acquisition-adjusted FCF turning positive and DSO returning to the high-50s; it flips to Avoid on a third consecutive working-capital draw or a differential vape-levy on refillable pods in the October 2026 Budget.

Catalysts — The Decision Calendar

The next six months hinge on two hard-dated prints and one regulatory ruling: the FY26 full-year results in mid-to-late June 2026 (the first clean full-year read of vape revenue post the 1 June 2025 disposable ban), the AGM in July/August (BDO 11-year reappointment vote and the new one-year SIP advisory vote), and the UK vape excise levy structure expected in the autumn 2026 fiscal event. The H1 FY27 trading update around mid-September is the early-warning bell for whether the new product mix is durable. The calendar is Medium quality — three dated events in the window, one of which (the levy) is a binary regulatory setter — and the rerating-or-derating debate effectively resolves inside this window. At 160p the stock is asymmetric to the upside if vape revenue holds and the levy lands at pod parity vs disposable; cheap for a reason if either leg fails.

Catalyst Setup

The calendar shape is front-loaded then back-loaded: a high-density June-July cluster (FY26 results + AGM), a quieter August window for tactical positioning, then the September-October cluster (H1 FY27 + levy) that sets up the FY27 narrative. August is the only month with no scheduled hard event — the natural window for any tactical re-sizing on bolt-on M&A or share-placement signals.

Ranked Catalyst Timeline

The ranking is decision-value, not chronology. The June 2026 print sits at #1 because it resolves three open debates simultaneously (vape durability, non-vape gross profit run-rate, acquisition-adjusted FCF) on the same day. The October 2026 vape levy ranks #2 despite further dating because the magnitude is larger — it sets 2027-2030 terminal value on the largest segment. The H1 FY27 update is #4 not #2 because it is a follow-on data point, not a thesis resolver — but it is the clearest 90-day window after June.

Impact Matrix

The matrix shows that only two events actually resolve the central debate (FY26 results and the levy). The AGM, the H1 FY27 update, and the M&A flywheel are credibility tests rather than thesis-breakers — they shift sizing, not direction.

Next 90 Days

The June 2026 print is the only hard-dated rerating event in the next 90 days. Everything else in this window is sizing-input material. The H1 FY27 trading update (~mid-September) and the levy ruling (October-November) sit outside the 90-day mark but inside the six-month window, and both are why the next 90 days are about positioning ahead of those resolutions, not waiting for them.

What Would Change the View

The two observable signals that most change the debate over the next six months are (1) non-vape gross profit at the FY26 print — clearing £40m would force the sell-side to lift FY27 EPS estimates and validate the "Manchester FMCG roll-up, not vape stock" framing the bull thesis rests on, while staying near £25m re-confirms the cheap-multiple regime; and (2) the structure of the autumn 2026 vape excise levy — pod-parity-with-disposable taxation removes the regulatory overhang on 56% of FY25 revenue and is a near-binary trigger for either a £2.40 rerate or a £1.20 reset. A third, governance-only signal carries asymmetric tail risk: a Sandy Chadha placement that breaks his stake below 55% would shift the People grade from B+ toward B and undermine the alignment leg of the bull case independently of the operating numbers. These three together resolve the Bull vs Bear contest more cleanly than any single earnings print could; the catalyst calendar is therefore Medium-quality and decision-relevant rather than thin or noisy.

The June 2026 print alone exposes the first four triggers; the AGM exposes one; the October-November fiscal event exposes the highest-magnitude one. A PM building or trimming a position should set explicit calendar reminders for late June (FY26), late July/early August (AGM result RNS), mid-September (H1 FY27 trading update) and end-October to mid-November (autumn fiscal event). Continuous monitoring is required only on the placement and M&A items, neither of which is calendarable.

The Full Story

Supreme is a 50-year-old Manchester FMCG distributor that spent four decades quietly compounding cash on a battery-and-lighting base, then in five public years compressed three transformations into one ticker. Sandy Chadha brought the business to AIM in February 2021 selling investors a vertically integrated value-FMCG platform. The narrative arc since has been driven almost entirely by vaping — first 88Vape e-liquid, then a 2023 ElfBar/Lost Mary distribution windfall that nearly doubled revenue, then the June 2025 UK disposable-vape ban that forced management to re-platform the company on weeks of notice. Credibility through that cycle has held up surprisingly well: management called the disposables risk early, pre-funded the diversification (Clearly Drinks, Typhoo, 1001, SlimFast) before the ban hit, and delivered FY25 inside its own raised guide. The current chapter is whether a deliberately rebuilt three-division platform — Vaping, Drinks and Wellness, Electricals and Household — can replace the disposable revenue without giving back the margin gains.

1. The Narrative Arc

The arc has three cleanly separable phases. Phase 1 (FY20–FY22): a cash-generative distributor running on batteries, licensed lighting (Energizer, JCB), 88Vape e-liquid, and early sports nutrition; revenue compounded mid-teens, EBITDA margin sat near 16%. Phase 2 (FY23–FY24): vaping became the engine. Revenue jumped 42% in FY24 to £221m and Adjusted EBITDA almost doubled to £38.1m, a near-step-change driven entirely by disposable vapes — own-brand 88Vape disposables plus the ElfBar/Lost Mary master-distribution agreement signed early calendar 2023. By FY24, disposables were 32% of group revenue (£70.7m). Phase 3 (FY25 onwards): management saw the regulatory cliff coming, pre-funded a re-platforming via Clearly Drinks (Aug 2024), Typhoo (Dec 2024), 1001 (Sep 2025) and SlimFast (Oct 2025), and absorbed the 1 June 2025 disposables ban with a successful transition to pod systems.

2. What Management Emphasized — and Then Stopped

The heatmap is the cleanest way to see the pivots. Quietly dropped: "COVID resilience" (FY21–22 only), and "international expansion" through Vendek/Republic of Ireland which was loud at IPO and is now barely mentioned. Quietly added: "M&A pipeline" went from a stated growth driver to the dominant vehicle — seven acquisitions in three years. Replaced wholesale: Disposable vapes and ElfBar were the leading words of FY24 commentary; by H1 FY26 they have been swapped for "pod transition" and "Drinks and Wellness." Stable: the 88Vape 10ml e-liquid hero product and the Energizer/JCB licensing model have been talked about every year since the IPO.

3. Risk Evolution

Three things stand out. First, the disposables-ban risk was on the page in FY22 and ramped every year — by FY25 it was rated the company's top regulatory exposure with the ban literally written into the risk factors. Management did not get caught flat-footed; they front-ran it. Second, lighting and batteries quietly migrated from "stable cash cow" to a structural-decline narrative — FY23 saw the first lighting revenue contraction in 15 years (-43%), and H1 FY26 disclosed Panasonic exiting the European battery market, forcing brand transition mid-year. Third, M&A integration risk has only one direction of travel. Seven acquisitions since 2021, and the H1 FY26 portfolio of brands (88Vape, Liberty Flights, Cuts Ice, Superdragon, Clearly Drinks, Typhoo, 1001, SlimFast) is materially more complex than the IPO prospectus business.

4. How They Handled Bad News

The FY23 lighting miss. Lighting revenue dropped from £27.0m to £15.4m — a category that had grown for 15 years. The CFO did not bury it. The FY23 commentary called it out in the first three paragraphs: "the first year of revenue contraction since the category commenced trading over 15 years ago." They named the cause (retailer overstocking after FY22) and forecast recovery in FY24 and FY25. Lighting did partially recover in FY24 (+7%) but then re-rolled in FY25 and was still soft in H1 FY26. The forecast was directionally wrong; the disclosure was honest.

The 1 June 2025 disposables ban. Disposables were £70.7m of group revenue in FY24 — almost a third of the company. Rather than hedge or downplay, management used FY24 and FY25 commentary to repeatedly flag it as a known forward step-down, raised the FY25 EBITDA guide to "at least £40m" in November 2024, then closed FY25 inside that guide, then reported H1 FY26 vaping up 13% YoY through the pod transition. The walk-from-disposables narrative was telegraphed and delivered. What was understated was the EBITDA-margin give-up: pod systems carry lower gross margin than disposables (H1 FY26 vape gross margin slipped from 33% to 31%).

5. Guidance Track Record

A 7 out of 10. Guidance has been cleanly delivered on every metric that matters — EBITDA, net-cash, mix-shift to non-vape, dividend policy after a transparent rebase from 50% to 25% of profits. The blemishes: a £240m FY25 revenue guide that came in at £231m, and a "lighting recovers" call that was directionally optimistic. Both misses were small; neither was concealed. The bigger trust signal is that the company called the disposables ban early, pre-funded the diversification, and absorbed a £70m product-line wipeout in one fiscal year without breaking covenants or cutting the dividend.

6. What the Story Is Now

The current story is no longer "UK vape distributor with a value-FMCG side-hustle." It is "Manchester FMCG roll-up with three roughly equal divisions — Vaping, Drinks and Wellness, Electricals and Household — pursuing earnings-enhancing UK consumer-brand acquisitions at single-digit EBITDA multiples and integrating them onto a vertically-owned distribution and manufacturing platform." Seven deals in five years. About half of annualised revenue is now non-vape after the SlimFast addition in October 2025.

De-risked: the binary disposables-ban event has passed and pod-system revenue is growing; net cash is intact; dividend policy is on its post-cut footing; the platform has demonstrated it can absorb and integrate a distressed acquisition (Typhoo, bought from administration with £4.1m of negative goodwill).

Still stretched: EBITDA margin guidance of 15% for FY26 is a material step down from the 17.5% FY25 print, and pod systems structurally carry less gross margin than disposables did. Lighting and batteries are now in clear secular decline (Panasonic exiting Europe, lightbulbs lasting longer). The investment case rests on Drinks and Wellness scaling from £48.8m in FY25 to a credible £75m+ run-rate, and the next two or three M&A targets being as accretive as Clearly Drinks proved to be.

What to believe: that management can keep buying small UK consumer brands cheaply and putting them through the Manchester platform — they have done it seven times, the cash conversion is real, and the disclosures have been straight. What to discount: that vaping returns to growth as a profit pool. The pod transition holds the unit volume, but the high-margin disposables era is done, and the remaining margin recovery has to come from elsewhere.

Financial Shenanigans

Supreme plc reports clean cash conversion, no auditor changes (BDO LLP since IPO), no restatements, and a consistent IFRS reporting framework. The forensic risk grade is Watch (28/100): the headline numbers are largely faithful, but three structural conditions warrant active monitoring — a 56% founder/CEO voting block on AIM, an acquisition-led FY24 receivables jump (revenue plus 42 percent vs receivables plus 70 percent), and a "bargain purchase" gain from the Typhoo Tea administration deal that flattered FY25 reported profit. None of these crosses into "earnings manipulation" on the available evidence; all three sit firmly in the "underwrite the disclosure" category. The single data point that would change the grade is independent confirmation that DSO normalises in H2 FY26 below 55 days; if it stays elevated, the reading moves to Elevated.

The Forensic Verdict

Cash conversion is a clear positive: three-year cumulative CFO of £71.5M exceeds cumulative net income of £57.9M (1.23x), and FCF before acquisitions converts NI at 1.06x. The accrual ratio of negative 1.3% in FY25 is firmly in clean territory. The forensic concerns are not in the income statement itself — they sit in receivables build, the bargain-purchase gain on Typhoo, an Adjusted EBITDA-only incentive plan that paid out 93% of max for both directors, and AIM-level governance with the founder controlling 56% of voting rights.

13-Shenanigan Scorecard

Breeding Ground

Supreme has the structural profile of a founder-led AIM company: thin governance bench, concentrated voting, simplified incentive plan with high payout, and a long-tenured auditor — all individually defensible, jointly worth a yellow flag.

The breeding ground amplifies — but does not create — the accounting risks below. Sandy Chadha's 55.98% holding means M&A decisions like the £25.6M FY25 spend on Clearly Drinks and Typhoo Tea face limited shareholder pushback. The FY24 LTIP grant to the CFO was structured around Absolute TSR (lapsed, share price did not clear hurdle) and EPS (vested in full), and FY25 onward replaces this with the simpler Supreme Incentive Plan capped at 200% of salary, weighted 80% Adjusted EBITDA. EBITDA-weighted plans favour acquisitive, integration-heavy strategies — exactly the path Supreme took with three acquisitions in 18 months (Clearly Drinks June 2024, Typhoo Nov 2024, SlimFast and 1001 in H1 FY26).

Earnings Quality

Reported earnings look largely faithful. The chief concerns are a divergence between revenue and receivables in FY24 and a non-recurring £2.9M bargain-purchase gain in FY25 that boosted reported PAT.

Revenue grew 42% in FY24 while receivables grew 70%, opening a 28-percentage-point gap. The FY24 annual report attributes this to the timing of large customer orders late in the period (Clearly Drinks closed June 2024 — only 9 months of trade receivables consolidated). FY25 closes that arithmetic, but DSO has stepped up to 62 days from a 47-49 day band.

Gross margin of 31.9% in FY25 is a five-year high, supported by mix shift toward higher-margin Drinks and Wellness (Clearly Drinks manufacturing margin disclosed at near 40%) and a deliberate retreat from lower-margin disposable vape distribution ahead of the 1 June 2025 ban. Operating margin held flat at 14.1% versus 14.5%, indicating SG&A absorbed most of the gross-margin lift — consistent with overhead onboarding from acquisitions (administrative expenses up £8M YoY). The pattern is consistent with management's narrative; nothing in the income-statement structure looks engineered.

The £2.9M FY25 bargain-purchase gain on Typhoo Tea is the largest single P&L item that needs to be stripped for run-rate analysis. Per the AR, it equals £4.1M of negative goodwill on acquisition less £1.2M of "ransom payments to key Typhoo suppliers". This is a real economic gain on a distressed acquisition, but it is non-recurring and, importantly, the company itself flags it inside Adjusted items rather than burying it in operating income.

Cash Flow Quality

Operating cash flow is durable. Management reports £25.1M of CFO in FY25, almost entirely consumed by £25.6M of net acquisition spend — meaning post-acquisition free cash flow turned slightly negative.

CFO has comfortably exceeded net income in 5 of 6 years. Pre-acquisition FCF tracks net income closely (£21.9M FCF vs £23.5M NI in FY25). The forensic test that matters is acquisition-adjusted FCF: it dropped from positive £15.6M in FY24 to negative £3.7M in FY25 because the company drew down its £11.6M cash balance to part-fund Typhoo and Clearly Drinks, and closing cash dropped to £3.2M.

The FY24 working-capital story is dominated by a £14.7M receivables build. FY25 added £6.6M more receivables and £11.9M of inventory build, partly funded by £6.4M of incremental payables. Inventory at year-end of £36.3M (FY24: £24.4M) is the highest in five years — and importantly, this is just before the 1 June 2025 disposable vape ban took effect. Some of this inventory is acquired Typhoo and Clearly Drinks stock (consolidated for the first time at year-end), but the vape inventory build at year-end is worth scrutinising in the FY26 accounts.

Net debt of £12.3M at FY25 (per AR) sits within HSBC's £40M asset-backed facility (£38M unutilised). The CFO disclosure that the group remains "net cash" of £1.2M on an Adjusted (ex-IFRS 16) basis is technically correct but is a reader-handling choice; on the balance sheet, the IFRS 16 lease liability of £13.4M is a real obligation.

Metric Hygiene

Supreme uses six non-GAAP measures (Adjusted EBITDA, Adjusted items, Adjusted PAT, Adjusted EPS, Adjusted net debt, Adjusted operating cash flow). The reconciliations are provided in the financial statements. The hygiene concern is the gap between Adjusted EPS and reported diluted EPS.

The Adjusted EPS premium has narrowed from 15% in FY24 to 11% in FY25 — actually a positive trend, suggesting management is not widening the non-GAAP wedge. The amortisation add-back is the largest component (acquired intangibles from Clearly Drinks and Typhoo), which is a defensible add-back for a serial acquirer. The bargain-purchase gain is correctly excluded from Adjusted PAT in FY25.

What to Underwrite Next

The forensic file does not change the thesis on Supreme. It does set five specific things to track over the next two reporting periods:

1. DSO normalisation in H1 FY26 and FY26 full year. FY25 DSO of 62 days (versus 47 days in FY23 and FY24) is the single biggest balance-sheet metric to watch. The H1 FY26 results are due in late November 2025; if DSO is below 55 days, the receivables jump was an acquisition timing artifact. If it stays at 60-plus, the next question is customer mix (concentration, payment terms, supplier finance) and whether the top-10 customers are paying slower.

2. FY26 inventory write-downs. Year-end inventory at £36.3M includes acquired Typhoo / Clearly Drinks stock and disposable vape inventory ahead of the 1 June 2025 ban. The H1 FY26 update reports vape sales up 13% to £76.9M with disposables shrinking from £10.0M to £4.4M — consistent with sell-through rather than write-down — but the FY26 annual report is the test.

3. Goodwill from Clearly Drinks (GBP 15.6M) and the Typhoo bargain-purchase gain. The Typhoo deal was struck out of administration with limited information; the £2.9M net bargain-purchase gain has to hold up through purchase-price allocation in the FY26 audit. Watch for any retroactive PPA adjustment or impairment trigger.

4. Acquisition-adjusted FCF. FY25 saw FCF after acquisitions of negative £3.7M. With H1 FY26 showing two more acquisitions (SlimFast £20.1M and 1001), FY26 acquisition-adjusted FCF needs to turn positive or the company is funding M&A through working capital and cash drawdown rather than recurring cash generation.

5. Independent challenge on M&A. Sandy Chadha's 55.98% voting power means deals do not meaningfully need disinterested-shareholder support. The four acquisitions in 18 months (Clearly Drinks, Typhoo, SlimFast, 1001) have all been struck quickly; the integration discipline is the test, and the early disclosure on Typhoo turnaround in the H1 FY26 update is encouraging but not yet validated by margin or returns data.

The accounting risk here is a position-sizing input, not a thesis breaker. It does not warrant a valuation haircut on its own — clean cash conversion, a long-tenured Big-Four-tier auditor (BDO LLP), and intact going-concern stress tests (the AR shows the group can absorb a 75% revenue decline before running out of cash) are real positives. But the combination of an AIM listing, founder voting control, EBITDA-weighted incentives, and a year-end balance sheet that absorbed three acquisitions does justify a watching brief: review the H1 FY26 results in late November 2025 with a focused eye on receivables, inventory, and acquisition-adjusted FCF before adding to position size. If H1 FY26 confirms DSO normalisation and clean inventory, the forensic grade can move toward Clean. If it does not, this becomes Elevated, and the next item to investigate is the customer concentration (top 10 customers are over half of revenue per AR risk factors).

People & Governance

Grade: B+. A founder-CEO with 56% of the equity and a CFO who built her reputation taking another UK FMCG name (B&M) through IPO is a strong alignment story. The drag is structural: AIM-listed with QCA Code (lighter than Main Market), a single-incentive plan that swapped a 3-year LTIP for a 1-year bonus, no internal audit function, and an 11-year auditor relationship that is overdue for tender.

The People Running This Company

The bench is thin but credible. Chadha is unambiguously the operator — he built the company from nothing, knows every category, and his hands-on style is repeatedly named as a key person risk in the board's own evaluation. Smith and McDonald are the trust pillars: both came out of B&M, the UK's leading discount variety retailer, which gives them direct line of sight on Supreme's principal customer and on the working-capital and asset-based-lending mechanics that fund the M&A. Lord brings deal expertise the M&A-heavy strategy needs. The structural weakness is succession depth: the board itself flagged in March 2025 that emergency cover and divisional leadership below the executives is insufficient.

What They Get Paid

CEO total compensation of £631k is modest for a 56% owner of a £180-200m market-cap business — Chadha's payday is dividends and share-price appreciation, not salary. The CFO's £642k overtook the CEO in FY25 because the CFO uniquely participates in deferred-share SIP and a maturing 2022 LTIP (50% vested on the EPS leg; absolute-TSR leg lapsed). Pay scaled with performance: adjusted EBITDA hit £40.5m, triggering 100% of the EBITDA element; the strategic/personal element scored 13.33% of a 20% maximum, for an aggregate 93.33% payout.

Are They Aligned?

Chadha's 55.98% stake gives him absolute control of every ordinary resolution and effective control of every special resolution at any AGM where free float turnout is incomplete. Three institutions (Moneta, Slater, Bronte) and Hargreaves Lansdown's retail aggregation hold roughly 20% — meaningful enough to push back, but unable to outvote the founder.

The wealth ratio is the alignment story: Chadha's stake is roughly 300 times his annual salary. Every penny of share-price movement matters more to him than any incentive plan the RemCo could design.

The December 2025 founder sale of 1.6m shares to a single institutional buyer at 160p is the only material insider transaction since IPO. Two interpretations: (1) liquidity provision to satisfy demand, leaving Chadha still controlling at 56.31% — benign; (2) modest profit-taking after a recovery in the share price from sub-125p in early FY25 to 160p+ in late 2025. Either way the proceeds (~£2.6m) are immaterial against the remaining stake. The CFO's 21,000-share open-market buy at 101p in May 2023 was a confidence signal during a sharp drawdown and worked: those shares are now worth ~50% more.

Dilution is contained. Outstanding director options total 3.24m (CEO 2.91m subject to performance criteria, all from IPO grant; CFO 0.33m). Against 117.3m shares in issue this is 2.8% — typical for AIM. The CEO's IPO options are expected to lapse in FY26, which will reduce dilution. The new SIP defers up to 50% of bonus into shares vesting over 3 years but caps at 200% of salary, so annual share dilution will be tiny.

Related-party items are referenced in Note 28 of the AR but no specific items were extracted into the structured data. The relationship agreement with Sandy Chadha as controlling shareholder has been in place since IPO 2021 and is the standard AIM tool for protecting minority shareholders. One material related-party flag: Chair Paul McDonald holds shares in B&M, which is a material customer of Supreme. The board has formally concluded this does not compromise his independence; minority shareholders should monitor disclosure of any large B&M-Supreme commercial decisions.

Skin-in-the-game score: 7.5/10. Penalised from 9 mainly because the alignment is concentrated in one person; Smith, the directors who advise her, and the broader management team have token holdings. If Chadha steps back the alignment story disappears overnight.

Board Quality

'role' is not a column in the dataset

Independence: 3 of 5 (60%) — meets QCA Code recommendation that the majority is independent. Each NED chairs one of the three principal committees, all of which contain only the three independents. Attendance was perfect (9/9 board, 3/3 audit, 2/2 RemCo, 2/2 Nominations).

The committee chairs are well-matched to their remits: Lord (chartered accountant, M&A specialist) on Audit; Cashmore (former CEO of a Main Market company) on Remuneration; McDonald (FCCA, former CFO) on Nominations and overall stewardship. The board's explicit candour in flagging succession depth and divisional oversight as 2025 priorities is constructive — it's the type of self-criticism a controlling-shareholder board often suppresses.

AGM 2025 Resolutions

The board's own statement notes "no significant proportion of votes have been cast against any resolution since the Company listed in 2021." With Chadha controlling 55.98%, that is structurally near-guaranteed — but the Pre-Emption Group-aligned share-allotment caps and the willingness to take Resolution 2 (remuneration) on an advisory vote are constructive signals.

The Verdict

Letter grade: B+.

The strongest positives are owner-operator alignment (B+ becomes A- if you weight skin-in-the-game heavily) and a CFO/Chair pairing that has done this job before at B&M. The real concerns are the new one-year incentive plan (a downgrade from a 3-year LTIP), a stale audit relationship, no internal audit, and key-person dependency that the board itself acknowledges.

The single thing that would most likely move the grade: a competitive audit tender combined with reinstating a multi-year performance share element to the SIP would push this to A-. A material related-party transaction surfacing in Note 28, or any sign Chadha is reducing his stake materially below 50%, would push it to B.

Web Research — What the Internet Knows

The Bottom Line from the Web

The web confirms what the filings imply but won't say outright: Supreme is a founder-controlled, AIM-listed roll-up whose vape windfall is being deliberately diluted into soft drinks, tea, and weight-management brands before regulation re-prices the cash cow. The single most important off-filing data point is the December 2025 founder share placement — Sandy Chadha sold 2.0m shares (~£3.1m) yet still controls 56.31% of the equity, signalling personal liquidity, not loss of conviction. The external valuation context is equally striking: independent screens peg SUP at roughly 0.8x EV/Revenue and 5.1x EV/EBITDA on LTM (multiples.vc, May 2026) versus a 12-month consensus price target of 229.5p — well above the ~150p where the shares are trading.

What Matters Most

Acquisition cadence has stepped up materially. Within 14 months Supreme has closed Clearly Drinks (Aug 2024, ~£15m), Typhoo Tea from administration (Dec 2024, £10.2m / $12.94m per Reuters), 1001 carpet care (Sep 2025), and SlimFast UK & Europe (Oct 2025, £20.1m per Investing.com). The Typhoo deal generated a ~£2.9m bargain-purchase gain because it was bought from administration — distinct from goodwill but a reminder these are distressed-asset deals that need integration proof.

Consensus price target sits well above the tape. Fintel reports a one-year average price target of 229.5p (range 227.25–236.25p) versus a current ~150p print — implying ~50% upside if consensus is right, but coverage is thin (Simply Wall St explicitly notes the stock is "probably not widely covered"). Source: fintel.io.

FY26 Q2 result missed consensus by a hair. TipRanks recorded the 25 Nov 2025 H1 earnings release at 0.091p EPS vs 0.095p consensus (–0.004p miss), even as half-year revenue grew to £118.09m (+29.8% YoY). The miss is small but matters for a stock priced for accelerating diversification. Source: tipranks.com, stockanalysis.com.

Gross margin step-up to ~31% appears structural. Multiples.vc (May 2026) shows LTM gross margin of 31% and EBITDA margin of 15% (vs prior FY of 18%), consistent with the Clearly/Typhoo mix-shift narrative. The EBITDA margin compression LTM-vs-FY needs watching: it could be integration cost or it could be the disposable-ban transition.

Long-running independent bull case (Trident Opportunities Substack, Apr 2024 + Jul 2024 update). Independent investor write-up framed Supreme as a vertically integrated FMCG distributor at 3.5x EV/EBITDA, with Vaping then 49% of revenue and Branded Distribution (ElfBar/Lost Mary) as the FY24 growth engine. Stock has roughly doubled since the original 120p pitch. The author argued the disposable ban would be "more of a non-event" — a thesis the FY26 H1 numbers tentatively support.

Recent News Timeline

What the Specialists Asked

The specialists submitted 30 targeted questions for web verification. With Phase-2 web fetch skipped on this ultralight run, answers below are best-effort synthesis from the four phase-1 research files (61 Brave queries, 40 page fetches).

Insider Spotlight

Web research is consistent across SimplyWallSt (Sep 2024, Feb 2025), Companies House and Yahoo Finance: Sandy (Sandeep Singh) Chadha is CEO since Dec 2017, Person-with-Significant-Control, and the dominant gravitational force on the share register.

SimplyWallSt: "Sandy's compensation has been consistent with company performance over the past year."

The CFO purchase in May 2023 (21,000 shares at ~130p) is small but directionally positive. The two CEO placements bracket the most aggressive M&A burst in the company's history — consistent with personal liquidity raising rather than loss of conviction, given residual 56.31% control.

Industry Context

The web reveals three structural forces shaping the FMCG distribution category Supreme operates in:

1. UK vaping regulation in transition. Disposable ban (1 Jun 2025) is in effect; the 2026 vape excise duty and the structural shift to refillable pods are the next legislative dominos. Independent commentary (Trident, Apr 2024) and management's own pod-parity argument frame the ban as a re-platforming event rather than a demand event.
2. Distressed-asset opportunity in UK consumer brands. Typhoo Tea (administration), 1001, and SlimFast all came at non-strategic prices, reflecting the broader stress in mid-tier UK consumer brands. Supreme's vertically integrated distribution model (substack thesis) makes it a logical buyer of orphan brands needing a route-to-shelf.
3. AIM small-cap discount persists. External screens consistently price SUP at ~5x EV/EBITDA versus 8–12x for AIM consumer comps with deeper liquidity. The web debate frames this as a structural AIM/free-float discount layered on a vape-overhang discount — both of which compress over time if the diversification thesis plays out.

Liquidity & Technicals — Supreme PLC (SUP.L)

The liquidity verdict is specialist-only: even at an aggressive 20% ADV participation rate, a fund can only execute about £189k of stock over a five-day window, which caps the practical implementable position at well under one percent of any meaningful AUM. The tape itself is constructive on near-term momentum (RSI riding 70, MACD histogram positive and accelerating) but trapped under a still-falling 200-day average, leaving the stock in a counter-trend bounce within a broken longer-term setup.

1. Portfolio implementation verdict

The stance score nets to about minus one: trend (price under a falling 200d), relative strength, and volume regime are unconstructive; momentum and the recent 50/200 dynamic are short-term constructive; volatility and 52-week position are neutral. The technical message and the liquidity message point in the same direction — wait or build slowly.

2. Price snapshot strip

Beta is shown as a proxy because no formal benchmark regression is computed in the data pack; for an AIM consumer-staples distributor the realised co-movement with the broad UK index is structurally low and noisy. The 52-week percentile of 44 says the stock is essentially mid-range — neither breaking out nor breaking down — and the YTD profile is a round-trip rather than a directional move.

3. The critical chart — full-history price with 50/200-day moving averages

The current 160p close sits 0.7% below the 200-day SMA of 161.1p — formally below trend, but within the no-man's-land band and not far from a reclaim. The 50-day at 141.3p is rising sharply off the February 2026 low, confirming the near-term bounce, but is still well under the 200-day, so the longer regime remains a sideways-to-down channel between roughly 124p and 205p with no demonstrated breakout in either direction. The five-year frame (2021 IPO debut at 150p, ATH 245p in mid-2021, ATL 72.5p in September 2023) shows two distinct regimes separated by the 2022–2023 derate, with current price still well below the cycle high.

4. Relative strength versus the broad market

What the rebased line does show: Supreme rallied roughly 60% from the May-2023 base to mid-2025, gave back most of the gain into early 2026, and is now back to a 54% cumulative return over three years — well behind the rebased mid-2025 peak. Against UK consumer staples broadly, that profile has been a laggard since the second half of 2025; the absence of a benchmark line means the magnitude of the relative drag is qualitative rather than quantified.

5. Momentum panel — RSI(14) and MACD histogram

RSI(14) is at 70.7, sitting right on the conventional overbought line after a clean V-shape from 19 in early February. MACD histogram has crossed firmly positive (latest +1.87 after a print of +4.09 mid-rally) and is rolling slightly off its peak — the standard pattern of a momentum impulse fading at the second derivative even as the first derivative remains constructive. Net read for the next one to three months: short-term momentum is bullish but no longer fresh; a single weak session could put RSI back in the 60s and the histogram into deceleration. There is no bearish divergence in the immediate window — price highs and oscillator highs tracked together — but neither is there confirmation that this is the start of a new bull leg rather than a relief rally.

6. Volume, volatility and sponsorship

The five most recent unusual-volume sessions cluster on red rather than green days — the November 2025 flush at 156p and the February 2026 print at 148p both came on 14× and 11× normal volume, which is the print pattern of forced selling more than fundamental re-rating. The single notable up-day spike was the July 2025 push to 190p on roughly 10× volume, and that level has since been ceded. Tape sponsorship is therefore mixed: there are buyers, but they have not yet absorbed the most recent supply.

The current realised vol of 37.1% sits essentially on the five-year median (37.7%) and well inside the p20–p80 normal band of 27.9% to 52.0%. The ATR(14) of 2.5p on a 160p stock is roughly a 1.6% daily true range, consistent with the 0.91% median 60-day intraday range — the tape is moving, but it is not stressed by historical standards and is not pricing a binary catalyst. Compression below the p20 line of 27.9% would historically have preceded directional moves; current vol is not yet at that compressed regime.

7. Institutional liquidity panel

A. ADV and turnover

ADV 60d is materially higher than ADV 20d (212k vs 118k), reflecting the volume cluster around the late-2025 sell-off; the 20-day figure is the more conservative and the more relevant for a build today. Annual turnover of 38% — one in roughly 2.6 years — confirms a stock dominated by long-term holders and management/family control rather than active institutional rotation.

B. Fund-capacity table

This is the table that decides the conversation. Even at 20% ADV — already an aggressive participation rate for AIM — a five-day build clears just £189k. A 5% portfolio weight is therefore only viable for funds under roughly £3.8m, and a 2% weight for funds under £9.5m. Anything resembling a UK small-cap fund (£50m+) is capacity-constrained out of any meaningful single-week entry.

C. Liquidation runway

A 1% issuer-level holding takes roughly two and a half months to liquidate at 20% ADV and over four months at 10% ADV. There is no scenario in this table where a fund with a meaningful percent-of-issuer position can reduce risk inside a single quarter without moving the print materially.

D. Price-range proxy

The median 60-day intraday range is 0.91%, which is inside the 2% threshold above which intraday impact cost becomes a separate concern. Friction here is the absolute size of ADV, not the bid-ask or daily range — the stock trades cleanly when it trades, but it does not trade enough.

Verdict. The largest size that genuinely clears a five-day build at 20% ADV is roughly £190k of stock, equivalent to under 0.1% of issuer market cap; at the more conservative 10% ADV cap, that drops to around £95k. A fund that wants real exposure must accept either a multi-week patient build via crossings and ADV-paced algos, or a sourced block from a long-term holder.

8. Support / resistance map and technical scorecard

Stance — neutral on a 3-to-6 month horizon

The setup is a counter-trend bounce inside a broken longer-term picture. Momentum says higher, trend says lower, volume says supply has not been cleared, and liquidity says it does not matter for institutional sizing because the stock cannot absorb meaningful order flow. The bullish case requires a decisive close above 175p — that reclaims the Bollinger upper band, the July 2025 high-volume cap, and forces the 200-day to stop falling. The bearish case re-asserts itself on a close below 141p — a clean break of the 50-day SMA from above with the death cross still in place would re-open 124p as the obvious target and 116p as the volatility-band floor.

Liquidity is the constraint. The correct action for any fund larger than roughly £10m of AUM is watchlist only; for specialist UK small-cap mandates that can stomach multi-week building, the entry strategy is patient, ADV-paced accumulation between 141p (50-day support) and 160p (spot), with an explicit pre-trade understanding that a 1% issuer position will take a quarter or more to unwind if the thesis breaks.

The most-recent technical setups for an investor sizing a position: (1) the November 2025 death cross is the dominant medium-term signal and has not been invalidated; (2) the February 2026 capitulation low at 124p, printed on 11× volume, is the line in the sand for the bear case; (3) the current RSI/MACD impulse is a counter-trend rally to be sold into, not bought into, until 175p clears; (4) a tightening daily range (ATR roughly 2.5p) inside the 124–175p envelope is the early-warning trigger for the next directional move; (5) ADV remains the binding constraint on any institutional sizing decision regardless of which way the next signal breaks.